<DOC>
	<DOCNO>NCT01211782</DOCNO>
	<brief_summary>The study evaluate safety &amp; efficacy AC-1204 , ketogenic compound , administer orally daily basis 6 month . Following 6 month double-blind phase study , subject may enroll optional 6 month open-label extension phase . Efficacy evaluate standard test memory cognition , along measurement activity daily live quality life . Safety assess frequency adverse event change laboratory test result . Subjects stratify outcome separately analyze base apolipoprotein E4 genotype ( APOE4 ) .</brief_summary>
	<brief_title>AC-1204 Long-term Efficacy Response Trial ( ALERT Protocol )</brief_title>
	<detailed_description>Two primary outcome measure assess APOE4 ( - ) patient : 1. difference baseline AC-1204 placebo group ' ADAS-cog score 6 month 2. difference baseline AC-1204 placebo group ' CIBIC+ score 6 month Secondary endpoint include difference AC-1204 &amp; placebo group ' score instrument 3 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Males/females age 55 85 year MMSE score 1626 Probable mild moderate AD Presence CNS disorder alternative cause dementia Type 1 Type 2 diabetes Significant renal/hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>AD</keyword>
	<keyword>AC-1204</keyword>
	<keyword>ketogenic</keyword>
	<keyword>ketosis</keyword>
</DOC>